RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor

Structure

Volumn 20, Issue 11, 2012, Pages 1971-1982

  Nelson, Christopher A ^a   Warren, Julia T ^a   Wang, Michael W H ^a   Teitelbaum, Steven L ^a   Fremont, Daved H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; BINDING SITES; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RANK LIGAND; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84868567803     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2012.08.030     Document Type: Article

References (60)

1. P.D. Adams, P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.-W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, and A.J. McCoy PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Cryst. D66 2010 213 221
2. D.M. Anderson, E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. Tometsko, E.R. Roux, M.C. Teepe, R.F. DuBose, D. Cosman, and L. Galibert A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 390 1997 175 179
3. A.P. Armstrong, M.E. Tometsko, M. Glaccum, C.L. Sutherland, D. Cosman, and W.C. Dougall A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function J. Biol. Chem. 277 2002 44347 44356
4. M.F. Bachmann, B.R. Wong, R. Josien, R.M. Steinman, A. Oxenius, and Y. Choi TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation J. Exp. Med. 189 1999 1025 1031
5. T.M. Baetu, and J. Hiscott On the TRAIL to apoptosis Cytokine Growth Factor Rev. 13 2002 199 207
6. D.W. Banner, A. D'Arcy, W. Janes, R. Gentz, H.J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation Cell 73 1993 431 445
7. J.L. Bodmer, P. Schneider, and J. Tschopp The molecular architecture of the TNF superfamily Trends Biochem. Sci. 27 2002 19 26
8. B.F. Boyce, and L. Xing Functions of RANKL/RANK/OPG in bone modeling and remodeling Arch. Biochem. Biophys. 473 2008 139 146
9. N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W. Xu, and D.L. Lacey Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev. 12 1998 1260 1268
10. B. Chong, M. Hegde, M. Fawkner, S. Simonet, H. Cassinelli, M. Coker, J. Kanis, J. Seidel, C. Tau, B. Tüysüz International Hyperphosphatasia Collaborative Group Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype J. Bone Miner. Res. 18 2003 2095 2104
11. Collaborative Computational Project, Number 4 The CCP4 suite: programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50 1994 760 763
12. M. Degli-Esposti To die or not to die - the quest of the TRAIL receptors J. Leukoc. Biol. 65 1999 535 542
13. W.C. Dougall, M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M.E. Tometsko, and C.R. Maliszewski RANK is essential for osteoclast and lymph node development Genes Dev. 13 1999 2412 2424
14. J.G. Emery, P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, C. Silverman, E. Dul, E.R. Appelbaum, C. Eichman, and R. DiPrinzio Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J. Biol. Chem. 273 1998 14363 14367
15. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60 2004 2126 2132
16. J.E. Fata, Y.Y. Kong, J. Li, T. Sasaki, J. Irie-Sasaki, R.A. Moorehead, R. Elliott, S. Scully, E.B. Voura, and D.L. Lacey The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development Cell 103 2000 41 50
17. R. Hanada, A. Leibbrandt, T. Hanada, S. Kitaoka, T. Furuyashiki, H. Fujihara, J. Trichereau, M. Paolino, F. Qadri, and R. Plehm Central control of fever and female body temperature by RANKL/RANK Nature 462 2009 505 509
18. T. Hehlgans, and K. Pfeffer The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games Immunology 115 2005 1 20
19. S.G. Hymowitz, H.W. Christinger, G. Fuh, M. Ultsch, M. O'Connell, R.F. Kelley, A. Ashkenazi, and A.M. de Vos Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5 Mol. Cell 4 1999 563 571
20. S.G. Hymowitz, M.P. O'Connell, M.H. Ultsch, A. Hurst, K. Totpal, A. Ashkenazi, A.M. de Vos, and R.F. Kelley A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL Biochemistry 39 2000 633 640
21. S. Ito, K. Wakabayashi, O. Ubukata, S. Hayashi, F. Okada, and T. Hata Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution J. Biol. Chem. 277 2002 6631 6636
22. S. Jabbar, J. Drury, J.N. Fordham, H.K. Datta, R.M. Francis, and S.P. Tuck Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis J. Clin. Pathol. 64 2011 354 357
23. L.A. Kelley, R.M. MacCallum, and M.J. Sternberg Enhanced genome annotation using structural profiles in the program 3D-PSSM J. Mol. Biol. 299 2000 499 520
24. N. Kim, P.R. Odgren, D.K. Kim, S.C. Marks Jr., and Y. Choi Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene Proc. Natl. Acad. Sci. USA 97 2000 10905 10910
25. Y.Y. Kong, H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, S. Morony, A.J. Oliveira-dos-Santos, G. Van, and A. Itie OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
26. E. Krissinel, and K. Henrick Inference of macromolecular assemblies from crystalline state J. Mol. Biol. 372 2007 774 797
27. D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, and S. Scully Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
28. J. Lam, C.A. Nelson, F.P. Ross, S.L. Teitelbaum, and D.H. Fremont Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity J. Clin. Invest. 108 2001 971 979
29. R.A. Laskowski, and M.B. Swindells LigPlot+: multiple ligand-protein interaction diagrams for drug discovery J. Chem. Inf. Model. 51 2011 2778 2786
30. M.C. Lawrence, and P.M. Colman Shape complementarity at protein/protein interfaces J. Mol. Biol. 234 1993 946 950
31. A. Leibbrandt, and J.M. Penninger RANK/RANKL: regulators of immune responses and bone physiology Ann. N Y Acad. Sci. 1143 2008 123 150
32. A. Leibbrandt, and J.M. Penninger RANK(L) as a key target for controlling bone loss Adv. Exp. Med. Biol. 647 2009 130 145
33. J. Li, I. Sarosi, X.Q. Yan, S. Morony, C. Capparelli, H.L. Tan, S. McCabe, R. Elliott, S. Scully, and G. Van RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism Proc. Natl. Acad. Sci. USA 97 2000 1566 1571
34. C. Liu, T.S. Walter, P. Huang, S. Zhang, X. Zhu, Y. Wu, L.R. Wedderburn, P. Tang, R.J. Owens, and D.I. Stuart Structural and functional insights of RANKL-RANK interaction and signaling J. Immunol. 184 2010 6910 6919
35. R.M. Locksley, N. Killeen, and M.J. Lenardo The TNF and TNF receptor superfamilies: integrating mammalian biology Cell 104 2001 487 501
36. I.K. McDonald, and J.M. Thornton Satisfying hydrogen bonding potential in proteins J. Mol. Biol. 238 1994 777 793
37. A. Mizuno, N. Amizuka, K. Irie, A. Murakami, N. Fujise, T. Kanno, Y. Sato, N. Nakagawa, H. Yasuda, and S. Mochizuki Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin Biochem. Biophys. Res. Commun. 247 1998 610 615
38. J. Mongkolsapaya, J.M. Grimes, N. Chen, X.N. Xu, D.I. Stuart, E.Y. Jones, and G.R. Screaton Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation Nat. Struct. Biol. 6 1999 1048 1053
39. J.H. Naismith, and S.R. Sprang Modularity in the TNF-receptor family Trends Biochem. Sci. 23 1998 74 79
40. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collected in oscillation mode C.W. Carter Jr. R.M. Sweet, Methods in Enzymology 1997 Academic Press New York 307 326
41. P. Reid, and I. Holen Pathophysiological roles of osteoprotegerin (OPG) Eur. J. Cell Biol. 88 2009 1 17
42. J. Schlöndorff, L. Lum, and C.P. Blobel Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase J. Biol. Chem. 276 2001 14665 14674
43. L.A. Schneeweis, D. Willard, and M.E. Milla Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand J. Biol. Chem. 280 2005 41155 41164
44. L. Schrodinger The PyMOL Molecular Graphics System, Version 1.5.0.1 2012 Schrodinger, LLC
45. J. Schymkowitz, J. Borg, F. Stricher, R. Nys, F. Rousseau, and L. Serrano The FoldX web server: an online force field Nucleic Acids Res. 33 Web Server issue 2005 W382 W388
46. E. Seeman Bone modeling and remodeling Crit. Rev. Eukaryot. Gene Expr. 19 2009 219 233
47. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, R. Lüthy, H.Q. Nguyen, S. Wooden, L. Bennett, and T. Boone Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
48. H.M. Ta, G.T. Nguyen, H.M. Jin, J. Choi, H. Park, N. Kim, H.Y. Hwang, and K.K. Kim Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis Proc. Natl. Acad. Sci. USA 107 2010 20281 20286
49. S.L. Teitelbaum Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170 2007 427 435
50. A. Truneh, S. Sharma, C. Silverman, S. Khandekar, M.P. Reddy, K.C. Deen, M.M. McLaughlin, S.M. Srinivasula, G.P. Livi, and L.A. Marshall Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor J. Biol. Chem. 275 2000 23319 23325
51. A. Wasilewska, A. Rybi-Szuminska, and W. Zoch-Zwierz Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children Pediatr. Nephrol. 25 2010 2067 2075
52. S.R. Wiley, K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, and C.A. Smith Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673 682
53. B.R. Wong, J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F.S. Bartlett 3rd, and W.N. Frankel TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells J. Biol. Chem. 272 1997 25190 25194
54. B.R. Wong, R. Josien, S.Y. Lee, M. Vologodskaia, R.M. Steinman, and Y.W. Choi The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor J. Biol. Chem. 273 1998 28355 28359
55. S. Xu, Y. Wang, J. Lu, and J. Xu Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis Rheumatol. Int. 2011 10.1007/s00296-011-2175-5 Published online November 6, 2011
56. K. Yamaguchi, M. Kinosaki, M. Goto, F. Kobayashi, E. Tsuda, T. Morinaga, and K. Higashio Characterization of structural domains of human osteoclastogenesis inhibitory factor J. Biol. Chem. 273 1998 5117 5123
57. H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, and A. Murakami Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL Proc. Natl. Acad. Sci. USA 95 1998 3597 3602
58. M. Zaidi Skeletal remodeling in health and disease Nat. Med. 13 2007 791 801
59. G. Zauli, E. Melloni, S. Capitani, and P. Secchiero Role of full-length osteoprotegerin in tumor cell biology Cell. Mol. Life Sci. 66 2009 841 851
60. C. Zhan, Y. Patskovsky, Q. Yan, Z. Li, U. Ramagopal, H. Cheng, M. Brenowitz, X. Hui, S.G. Nathenson, and S.C. Almo Decoy strategies: the structure of TL1A:DcR3 complex Structure 19 2011 162 171